"10.1371_journal.pone.0036506","plos one","2012-05-01T00:00:00Z","Marijke van Rikxoort; Martin Michaelis; Markus Wolschek; Thomas Muster; Andrej Egorov; Joachim Seipelt; Hans Wilhelm Doerr; Jindrich Cinatl","Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany; AVIR Green Hills Biotechnology, Vienna, Austria","Conceived and designed the experiments: MvR MM MW JC TM JS AE HWD. Performed the experiments: MvR MW. Analyzed the data: MvR MM TM JS JC MW. Contributed reagents/materials/analysis tools: MW JS TM AE HWD. Wrote the paper: MvR MM HWD.","AVIR Green Hills Biotechnology is a privately held biopharmaceutical company based in Vienna (Austria) that develops and commercializes novel influenza vaccines, and novel therapeutics against infectious diseases and cancer. The most advanced product of AVIR is deltaFLU, an intranasal vaccine against influenza which is in Phase II clinical trials. MW, TM, AE and JS were employees of AGHB at the time of study. TM, JS and AE are shareholders of AVIR, TM is CEO/CSO. IPR rights related to this manuscript are covered by patent rights from AVIR Green Hills. In adherence to the PLoS guidelines, AVIR Green Hills will make freely available any materials and information described in the publication that are reasonably requested by others for the purpose of academic, non-commercial research. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","05","Marijke van Rikxoort","MVR",8,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
